Hospira, a pharmaceutical and medication delivery company, has reported net sales of $968m for the second quarter ended June 30, 2010, an increase of 1.2%, compared to $956.9m for the comparable period in 2009.
Hospira has posted an increase of 227.5% net income of $83.5m for the second quarter 2010, or $0.49 per diluted share, compared to $25.5m, or $0.16 per diluted share, for the comparable period in 2009.
For the six months ended June 30, 2010, Revenue of $1.97bn compared to $1.81bnm for the year ago period.
Hospira has posted a net income of $225.2m, or $1.34 per diluted share, compared to $191m, or $1.18 per diluted share, for the year ago period.
Christopher Begley, chairman and CEO of Hospira, said: “Hospira delivered another solid quarter, driven by strong performance in our Specialty Injectable Pharmaceuticals business and by continued momentum of our Project Fuel optimization initiatives.
“We made significant progress in advancing our business during the quarter, launching our first product from Hospira India, commercialising our second biosimilar product in Europe and strengthening our position in acute-care proprietary pharmaceuticals.
“We are highly focused on executing our strategy of investing for growth and improving margins and cash flow, as well as on driving quality improvements across our global manufacturing organisation. We remain on track to achieve our full-year earnings projections.”